SCHEMBL20320595

SCHEMBL20320595

O=c1[nH]c(-c2cccnc2)nc2cnccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 8/20 1.00
MAPT P10636 4/20 1.00
HPGD P15428 3/20 0.78
ALDH1A1 P00352 3/20 0.57
ALOX15 P16050 1/20 0.57
HSD17B10 Q99714 1/20 0.57
APOBEC3G Q9HC16 1/20 0.57
KDM4E B2RXH2 3/20 0.55
GAA P10253 1/20 0.55
RXFP1 Q9HBX9 1/20 0.55
TNKS O95271 1/20 0.55
PARP1 P09874 1/20 0.55
TNKS2 Q9H2K2 1/20 0.55
LDHA P00338 1/20 0.55
EPHX2 P34913 1/20 0.55
KDM5A P29375 1/20 0.52
NPC1 O15118 1/20 0.52
STAT1 P42224 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30527145 1.00 KDM4C (1.00) KDM4CMAPTHPGDALDH1A1ALOX15
Hydrochloric Acid SCHEMBL20303157 0.98 KDM4C (0.97) KDM4CMAPTHPGDALDH1A1ALOX15
Hydrochloric Acid SCHEMBL30002977 0.98 KDM4C (0.97) KDM4CMAPTHPGDALDH1A1ALOX15
SCHEMBL14344501 0.89 KDM4C (1.00) KDM4CMAPTHPGDALDH1A1ALOX15
SCHEMBL7280833 0.88 HPGD (1.00) KDM4CMAPTHPGDALDH1A1ALOX15
Hydrochloric Acid SCHEMBL28547770 0.87 HPGD (0.97) KDM4CMAPTHPGDALDH1A1ALOX15
SCHEMBL15645718 0.86 KDM4C (0.82) KDM4CMAPTHPGDALDH1A1ALOX15
SCHEMBL7289805 0.82 MAPT (0.69) KDM4CMAPTHPGDALDH1A1ALOX15
SCHEMBL9979126 0.82 KDM4C (0.71) KDM4CMAPTHPGDALDH1A1ALOX15
SCHEMBL15775362 0.81 KDM4C (0.74) KDM4CMAPTHPGDALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4252856-A2 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE Oligomerix, Inc. (US) 2023-10-04 EP disclosed
EP-3558950-B1 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE OLIGOMERIX INC (US) 2023-05-10 EP disclosed
US-20190345115-A1 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE OLIGOMERIX, INC. 2019-11-14 US disclosed
WO-2018118791-A9 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE OLIGOMERIX, INC. (US) 2019-08-22 WO disclosed
WO-2018118791-A2 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE OLIGOMERIX, INC. (US) 2018-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345115-A1 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE MAPT, PSEN1, APP KDM4C 2969/4885MAPT 1/4885HPGD 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.